Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Not listed Phase 4 Interventional

Usability, Immediate, and 30 Day Effect of External Neuromodulation With iTEAR100 Generation 2 in Dry Eye Patients

NCT05304637
View directory record Official record
Conditions
Dry Eye
Interventions
iTEAR100 treatment
Device
Lead sponsor
Olympic Ophthalmics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Issaquah, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

NCT03417505
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
Device
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Sacramento, California • Fort Lauderdale, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

NCT04084483
View directory record Official record
Conditions
Dry Eye Disease
Interventions
K-161, Placebo (Vehicle)
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

NCT00758784
View directory record Official record
Conditions
Dry Eye Disease
Interventions
bromfenac ophthalmic solution 0.06%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

A Study of TL-925 as a Treatment for Dry Eye Disease

NCT05745064
View directory record Official record
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Newport Beach, California • Colorado Springs, Colorado • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 4 Interventional

Oasys vs. Extreme H20 Xtra 59

NCT00477763
View directory record Official record
Conditions
Dry Eye
Interventions
Restasis, Refresh Endura
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
19 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hazleton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period

NCT00439400
View directory record Official record
Conditions
Dry Eye
Interventions
doxycycline, placebo
Drug
Lead sponsor
Alacrity Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Timeline
2007
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

NCT07054606
View directory record Official record
Conditions
Dry Eye
Interventions
Perfluorohexyloctane ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
San Diego, California • Longwood, Florida • Pittsburg, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 20, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diurnal Variation in Tear Osmolarity

NCT01321424
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Not listed
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Fairfield, Connecticut • Lynbrook, New York • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 20, 2026, 5:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
tofacitinib, Placebo
Drug · Other
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 4 Interventional

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

NCT03451396
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dry Eye Disease Study With Brimonidine

NCT03418727
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 4 Interventional

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

NCT01014078
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Azithromycin Ophthalmic Solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT07264517
View directory record Official record
Conditions
Dry Eye Disease
Interventions
GRF312 5%, Placebo Comparator
Drug · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Glendale, California • Grove, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 5:32 PM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Causes of Contact Lens Related Dry Eye

NCT00995189
View directory record Official record
Conditions
Contact Lens Related Dry Eye
Interventions
Opti-Free RepleniSH, ReNu MultiPlus, Contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 2Phase 3 Interventional

Study of TOP1630 for Dry Eye Syndrome

NCT03833388
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Drug
Lead sponsor
Topivert Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Lewiston, Maine • Andover, Massachusetts • Raynham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computer Screen Properties Study

NCT05042960
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Brightness
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Green Tea Lozenges for the Management of Dry Mouth

NCT01647737
View directory record Official record
Conditions
Xerostomia, Sjogren Syndrome, Dry Mouth
Interventions
MighTeaFlow, Xylitol
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 5:32 PM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 20, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

NCT01459588
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Eye Drop Formulation B, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops, Carboxymethylcellulose Based Lubricant Eye Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 20, 2026, 5:32 PM EDT